## 171,428,571 Shares of Voting Common Stock

This free writing prospectus relates only to the shares of voting common stock described below (the "Common Stock") and should be read together with the prospectus dated October 4, 2017 (including the documents incorporated by reference therein) relating to the offering, included in the Registration Statement on Form S-3 (File No. 333-220800) relating to these securities and the preliminary prospectus supplement dated December 18, 2018 (including the documents incorporated by reference therein) relating to this offering (together, the "Preliminary Prospectus"). The following information supplements and updates the information contained in the Preliminary Prospectus. Capitalized terms used but not defined herein have the meaning ascribed to them in the Preliminary Prospectus.

Symbol:GSAT (NYSE American)Size:S59,999,998,85Total Shares Offered:171,428,571 sharesOption to Buy Additional Shares:25,714,285 sharesPublic Offering Price:S0.35 per shareGross Spread:S0.00525 per shareNet Proceeds (after underwriting discounts and ourmissions and estimated expenses):S0.34475 per shareParticipation by Certain Existing Shareholders:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Marlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our commo stock at the public offering price for total settlement amounts of \$49.3 million, \$52. million and \$2.6 million, respectively, which include shares representing their respectively chaines of our commo stock at the public offering price for total settlement amounts of \$49.3 million, \$52. million and \$2.6 million, respectively, which include shares representing their respectively chaines, Follows, and 30%, respectively, before the offering.Use of Proceeds:As required under our Facility Agreement. Bo% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in a restricted account may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to pay the balance. The remainder of the proceeds from this offering will be ude for general coront may not be sufficient to pay the full amount of principal and interest due, in which case we will use<	Issuer:	Globalstar, Inc. (the "Company" or "we")
Total Shares Offered:17.1,428,571 sharesOption to Buy Additional Shares:25,714,285 sharesPublic Offering Price:S0.35 per shareGross Spread:S0.00525 per shareNet Price:S0.34475 per shareNet Price:S0.34475 per shareOmissions and estimated expenses):Porximately \$58,900,000 or approximately \$67,800,000 if the underwriter exercises its option to buy additional shares in full.Participation by Certain Existing Shareholder:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Wafander Asset Management ("Wafander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million nivestment, Thermo, Mudrick Capital and Wafander will beneficially own approximately \$6.5%, 6.0% and 3.0%, respectively, which include shares representing their respective por rata ownership and backstop commitment. Thermo is controlled by James Monroe III, our Executive Chairman. Following such a restricted account that may only be used to pay debt service obligations. We intend to use this amount, a restricted account that may only be used to pay debt service obligations. We intend to use this amount, a restricted account that may only be used to pay debt service obligations. We intend to use this amount, a restricted account that may only be used to pay debt service obligations. We intend to use this amount, a restricted account that may only be used to pay debt service obligations. We intend to use this amount, a restricted account the sup operceds to qualify as a Equity Cure Contribution, allowing use to a restricted account the sup	Symbol:	
Option to Buy Additional SharesSo Add SharesPublic Offering Price:S0.3025 per shareGross Spread:S0.00525 per shareNet Proceeds (after underwriting discound)S0.34475 per shareParticipation by Certain Existing Shareholder:Net Proceeds (after underwriting discound)Participation by Certain Existing Shareholder:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital Management, SP. 2011, 13, 849, 954 and 7,471, 153, respectively, shares of our common share are are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common shares are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common shares are et our purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common share and buy and purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common shares and an et are purchase 140, 970, 921, 14, 849, 954 and 7,471, 153, respectively, shares of our common shares and an eterase the purchase 140, 970, 982, 984, 984, 98	Size:	\$59,999,999.85
Public Offering Price:\$0.35 per shareGross Spread:\$0.00525 per shareNet Price:\$0.34475 per sharePartocceds (after underwriting discoutstand commissions and estimated expenses):Approximately \$58,900,000 or approximately \$67,800,000 if the underwriter exercises its option to burs additional shares in full.Participation by Certain Existing ShareholdersOur controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 1,849,954 and 7,471,153, respectively, shares of our common stock ar depublic offering price for total settlement amounts of \$49.3 million, AS5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo, Scontrolled by James Monroe III, our Executive Chairman. Following such an ansvestment, Thermo, Mudrick Capital and Warlander will beneficially own approximately \$65.%, 60% and 3.0%, respectively, lefore the offering.Use of Proceeds:As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited in the restricted account that may only be used to pay deb tervice obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercise account may not be sufficient to pay the balance. The remainder of the proceeds from this offering will be used for general account may not be sufficient to pay the full amount of principal and interest due, in which case we will use acat price pay be ubalance. The remainder of the proceeds from this	Total Shares Offered:	171,428,571 shares
Gross Spread50.0525 per shareNet Price:50.34475 per shareNet Proceeds (after underwriting discounts and commissions and estimated expenses):Approximately \$58,900,000 or approximately \$67,800,000 if the underwriter exercises its option to buy additional shares in full.Participation by Certain Existing Shareholder:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, which include shares representing their respective charinan. Following such an investment, Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, which and ever facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, to gether with cash on hand, to fund a principal and interest payment of approximately \$53 million due; proceember 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering proceed deposited in the restricted account may not be sufficient to pay the full amount of principal and interest day, in which case we will use cash on hand to pay the balance. The remainder of the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to quality as an Equity Care Contribution, allowing	Option to Buy Additional Shares:	25,714,285 shares
Net Price:\$0.34475 per shareNet Proceeds (after underwriting discounts and commissions and estimated expenses):Approximately \$58,900,000 or approximately \$67,800,000 if the underwriter exercises its option to buy additional shares in full.Participation by Certain Existing Shareholders:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo, Suchtick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compared to 53.0%, 5.6% and 2.8%, respectively, before the offering.Use of Proceeds:As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portio of the offering proceeds deposited in the restricted account may not be sufficient to pay the full amount of principal and interest payment of approximately \$53 million due in and restricted account that may only be used to gaudify as Equity Cure Contribution, allowing us to maintain compliance with the covenants under our F	Public Offering Price:	\$0.35 per share
Net Proceeds (after underwriting discounts and commissions and estimated expenses):Approximately \$58,900,000 or approximately \$67,800,000 if the underwriter exercises its option to buy additional shares in full.Participation by Certain Existing Shareholders:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$40.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compare to 53.0%, 5.6% and 2.8%, respectively, before the offering.Use of Proceeds:As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the proceeds to qualify as an Equity Cure Contribution, allowing us on and to pay the balance. The remainder of the proceeds from this offering will be used or general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us on maintain compliance with the covenants under our Facility Agreement as of December 31, 2018.Trade Date	Gross Spread:	\$0.00525 per share
commissions and estimated expenses):additional shares in full.Participation by Certain Existing Shareholders:Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo is controlled by James Monroe III, our Executive Chairman. Following such an investment, Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compared to 53.0%, 5.6% and 2.8%, respectively, before the offering.Use of Proceeds:As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering will be used for general corporate purposes. We also expect the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us to maintain compliance with the covenants under our Facility Agreement as of December 31, 2018.Trade Date:Wednesday, December 19, 2018Expected Closing Da	Net Price:	\$0.34475 per share
Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo is controlled by James Monroe III, our Executive Chairman. Following such an investment, Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compared to 53.0%, 5.6% and 2.8%, respectively, before the offering.Use of Proceeds:As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering proceeds deposited in the restricted account may not be sufficient to pay the full amount of principal and interest due, in which case we will use cash on hand to pay the balance. The remainder of the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us to maintain compliance with the covenants under our Facility Agreement as of December 31, 2018.Trade Date:Wednesday, December 19, 2018Expected Closing Date:Friday, December 21, 2018	ί θ	
a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering proceeds deposited in the restricted account may not be sufficient to pay the full amount of principal and interest due, in which case we will use cash on hand to pay the balance. The remainder of the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us to maintain compliance with the covenants under our Facility Agreement as of December 31, 2018.Trade Date:Wednesday, December 19, 2018Expected Closing Date:Friday, December 21, 2018	Participation by Certain Existing Shareholders:	Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of \$49.3 million, \$5.2 million and \$2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo is controlled by James Monroe III, our Executive Chairman. Following such an investment, Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compared
Trade Date:Wednesday, December 19, 2018Expected Closing Date:Friday, December 21, 2018	Use of Proceeds:	a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately \$53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering proceeds deposited in the restricted account may not be sufficient to pay the full amount of principal and interest due, in which case we will use cash on hand to pay the balance. The remainder of the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us to
	Trade Date:	Wednesday, December 19, 2018
Underwriter: Cantor Fitzgerald & Co.	Expected Closing Date:	Friday, December 21, 2018
	Underwriter:	Cantor Fitzgerald & Co.

The issuer has filed a Registration Statement on Form S-3 (including a prospectus) with the U.S. Securities and Exchange Commission (the "SEC"), which became effective on October 4, 2017. The issuer has also filed a preliminary prospectus, to which this communication relates, with the SEC on December 18, 2018. Before you invest, you should read the prospectus in the Registration Statement, the preliminary prospectus and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, the underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus if you request it from the underwriter: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.